Breaking News Instant updates and real-time market news.

GLPG

Galapagos NV

$58.91

-0.85 (-1.42%)

, ABBV

AbbVie

$59.45

-1.06 (-1.75%)

16:03
11/28/16
11/28
16:03
11/28/16
16:03

Galapagos initiates Phase 1 study that triggers milestone payment from AbbVie

Galapagos (GLPG) reported the initiation of a Phase 1 study in healthy volunteers with GLPG2737, a novel C2 corrector drug for cystic fibrosis. Initiation of the Phase 1 study triggers a $10M milestone payment from AbbVie (ABBV).

GLPG

Galapagos NV

$58.91

-0.85 (-1.42%)

ABBV

AbbVie

$59.45

-1.06 (-1.75%)

  • 03

    Dec

  • 05

    Dec

  • 14

    Dec

GLPG Galapagos NV
$58.91

-0.85 (-1.42%)

10/12/16
RBCM
10/12/16
NO CHANGE
RBCM
Outperform
Vertex competitor to report data soon, but has long way to go, says RBC Capital
RBC Capital analyst Michael Yee noted that Galapagos NV (GLPG) and partner AbbVie (ABBV) are likely to present new Phase IIa data for GLP-1837 for cystic fibrosis and host an analyst event on October 27, adding that he believes the data will likely be positive and suggest they are "on track" with progress on their triple pill. Yee adds it won't be surprising if Galapagos has positive '1837 "potentiator" data, as this is the easier of the components and only the first piece of a 3-pill drug. Vertex (VRTX) is also hosting an analyst event on Oct. 27 and will probably also give an update on its own "triple," said Yee, who thinks it should stay in the lead with most advanced triple. Yee keeps an Outperform rating on Vertex shares.
10/18/16
GSCO
10/18/16
UPGRADE
GSCO
Buy
Galapagos NV upgraded to Buy from Neutral at Goldman
10/27/16
JEFF
10/27/16
NO CHANGE
Target $102
JEFF
Buy
Jefferies sees Galapagos as reducing competitive concerns for Vertex
Jefferies analyst Brian Abrahams believes the "difficult to interpret" data from Galapagos (GLPG) should help reduce the "overdone" competitive concerns weighing on shares of Vertex Pharmaceuticals (VRTX). Galapagos' data for GLPG1837 show "possible signals of activity, but short study, small sample size, underdosing, and variability makes the results very difficult to conclusively interpret," Abrahams tells investors in a research note. The North American Cystic Fibrosis Conference highlights the early stage of any potential competitor and Vertex's "significant developmental lead time," the analyst contends. He reiterates a Buy rating on the shares with a $102 price target.
11/01/16
WBLR
11/01/16
DOWNGRADE
Target $81
WBLR
Market Perform
William Blair downgrades Vertex with competition looming
William Blair analyst Y. Katherine Xu downgraded Vertex Pharmaceuticals (VRTX) to Market Perform from Outperform after attending the North American Cystic Fibrosis Conference. Looming competition "has become more and more real," Xu tells investors in a research note. The triple combo in vitro data from Vertex, AbbVie (ABBV)/Galapagos (GLPG) and Proteostasis (PTI) appear comparable, Xu contends. The analyst expects "deteriorating pricing" for the Vertex's Cystic Fibrosis franchise starting in 2022 due to competition. She lowered her price target for the shares to $81 from $105. Vertex closed yesterday at $78.86.
ABBV AbbVie
$59.45

-1.06 (-1.75%)

11/08/16
BARD
11/08/16
NO CHANGE
Target $40
BARD
Outperform
Coherus Biosciences weakness a buying opportunity, says Baird
Baird analyst Michael Ulz noted Coherus (CHRS) received a decision denying the institution of the '166 IPR related to Abbie's (ABBV) Humira. Though the decision was disappointing, the analyst sees multiple opportunities remaining to circumvent the patent. Ulz said he would be a buyer on the weakness in Coherus and reiterated his Outperform rating and $40 price target on the shares.
11/28/16
SBSH
11/28/16
DOWNGRADE
SBSH
Neutral
AbbVie downgraded to Neutral from Buy at Citi
11/28/16
SBSH
11/28/16
DOWNGRADE
Target $60
SBSH
Neutral
Citi analyst 'perturbed,' downgrades AbbVie to Neutral
Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.
11/28/16
11/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Neutral from Buy at Citi. 2. Citi (C), Wells Fargo (WFC), and Regions Financial (RF) were downgraded to Hold from Buy at Jefferies with analyst Ken Usdin citing valuation. 3. Hilton (HLT) and Marriott (MAR) were downgraded to Hold from Buy at Evercore ISI. 4. H&R Block (HRB) downgraded to Sell from Neutral at BTIG with analyst Mark Palmer noting that President-elect Trump has said he wants to put H&R Block out of business by simplifying the tax code. 5. Tupperware Brands (TUP) downgraded to Sell from Neutral at B. Riley with analyst Linda Bolton Weiser saying the stock has not moved lower to reflect post-election currency devaluations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SBGSY

Schneider Electric

$13.70

-0.115 (-0.83%)

15:23
02/24/17
02/24
15:23
02/24/17
15:23
Conference/Events
Schneider Electric management to meet with JPMorgan »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 02

    Mar

AVP

Avon Products

$4.43

0.18 (4.24%)

15:21
02/24/17
02/24
15:21
02/24/17
15:21
Hot Stocks
Avon Products rises after COO discloses purchase of 150K shares »

Avon Products COO James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.53

-0.58 (-0.42%)

15:21
02/24/17
02/24
15:21
02/24/17
15:21
Options
Apple expiring ATM straddle is active as shares pin to $136 into the final hour »

Apple expiring ATM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

PPRUY

Kering

$24.38

0.055 (0.23%)

15:19
02/24/17
02/24
15:19
02/24/17
15:19
Conference/Events
Kering management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

$NSD

NASDAQ Market Internals

15:17
02/24/17
02/24
15:17
02/24/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
02/24/17
02/24
15:16
02/24/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$128.69

-1.04 (-0.80%)

15:14
02/24/17
02/24
15:14
02/24/17
15:14
Conference/Events
Aetna management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

WMT

Wal-Mart

$72.37

1.055 (1.48%)

, BBY

Best Buy

$45.75

1.435 (3.24%)

15:12
02/24/17
02/24
15:12
02/24/17
15:12
Periodicals
White House denying Cohn comments on border-adjustment tax, Axios says »

The White House has…

WMT

Wal-Mart

$72.37

1.055 (1.48%)

BBY

Best Buy

$45.75

1.435 (3.24%)

COST

Costco

$175.85

-0.66 (-0.37%)

TGT

Target

$66.59

1.61 (2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

PYPL

PayPal

$42.53

0.11 (0.26%)

15:11
02/24/17
02/24
15:11
02/24/17
15:11
Options
$1M premium seller in Paypal »

$1M premium seller in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

  • 21

    Mar

  • 22

    Mar

  • 27

    Mar

  • 28

    Mar

WSTC

West Corp.

$24.66

-0.09 (-0.36%)

15:09
02/24/17
02/24
15:09
02/24/17
15:09
Conference/Events
West Corp. to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FCNCA

First Citizens

$363.85

0.03 (0.01%)

15:07
02/24/17
02/24
15:07
02/24/17
15:07
Hot Stocks
Breaking Hot Stocks news story on First Citizens »

Vanguard reports 5.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLTR

Dollar Tree

$77.57

-0.97 (-1.24%)

15:06
02/24/17
02/24
15:06
02/24/17
15:06
Options
Dollar Tree call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

ADRO

Aduro Biotech

$11.15

-0.25 (-2.19%)

15:01
02/24/17
02/24
15:01
02/24/17
15:01
Hot Stocks
Meet Aduro: CEO Isaacs says partnerships help development efforts »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$1.42

-0.05 (-3.40%)

15:01
02/24/17
02/24
15:01
02/24/17
15:01
Hot Stocks
Breaking Hot Stocks news story on Sierra Oncology »

Frazier Healthcare VI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIGI

Endurance

$9.00

-0.3 (-3.23%)

14:59
02/24/17
02/24
14:59
02/24/17
14:59
Rumors
Rumor moving shares of Endurance »

Rumor: Endurance late day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

WSTC

West Corp.

$24.66

-0.09 (-0.36%)

14:57
02/24/17
02/24
14:57
02/24/17
14:57
Periodicals
West Corp. buyout looks challenging, Dealreporter says »

Private equity firms have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

LUK

Leucadia

$25.63

-0.09 (-0.35%)

14:50
02/24/17
02/24
14:50
02/24/17
14:50
Options
Leucadia options imply 2.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWJ

iShares MSCI Japan Index Fund

$51.43

-0.205 (-0.40%)

14:41
02/24/17
02/24
14:41
02/24/17
14:41
Options
iShares Japan Fund draws a notable option block »

iShares Japan Fund draws…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RP

RealPage

$33.70

-0.5 (-1.46%)

14:36
02/24/17
02/24
14:36
02/24/17
14:36
Conference/Events
RealPage management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 02

    Mar

VLKAY

Volkswagen

$30.91

0.135 (0.44%)

14:29
02/24/17
02/24
14:29
02/24/17
14:29
Hot Stocks
Volkswagen took EUR6.4B in charges from diesel scandal in FY16 »

Volkswagen said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADRO

Aduro Biotech

$11.15

-0.25 (-2.19%)

, NVS

Novartis

$77.15

-0.2959 (-0.38%)

14:27
02/24/17
02/24
14:27
02/24/17
14:27
Hot Stocks
Meet Aduro: Progress across 3 main platforms seen in 2017 »

In an exclusive interview…

ADRO

Aduro Biotech

$11.15

-0.25 (-2.19%)

NVS

Novartis

$77.15

-0.2959 (-0.38%)

JNJ

Johnson & Johnson

$122.09

1.19 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

  • 26

    Jun

SU

Suncor

$31.55

-1.12 (-3.43%)

14:26
02/24/17
02/24
14:26
02/24/17
14:26
Options
Suncor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$30.91

0.135 (0.44%)

14:21
02/24/17
02/24
14:21
02/24/17
14:21
Hot Stocks
Volkswagen sees FY17 operating return on sales 6%-7% »

The Volkswagen Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPKE

Spark Energy

$25.55

0.35 (1.39%)

14:21
02/24/17
02/24
14:21
02/24/17
14:21
Periodicals
Spark Energy hires Morgan Stanley to advise on potential sale, SparkSpread says »

Spark Energy has retained…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

VLKAY

Volkswagen

$30.91

0.135 (0.44%)

14:21
02/24/17
02/24
14:21
02/24/17
14:21
Earnings
Volkswagen reports FY16 EPS EUR10.24 vs (EUR3.20) last year »

Reports FY16 sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.